DIADEMA PARTNERS LP
MORRISTOWN, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$269.2M2026 Q3+ $511.2M options (notional, not included)
Positions148
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.38.4%
Top Holdings
VKTXPUT
Viking Therapeutics
5.7%
BMYCALL
Bristol Myers Squibb
4.8%
VKTXCALL
Viking Therapeutics
4.8%
VKTX 2 10-15-32
Viking Therapeutics
4.2%
KODPUT
Kodiak Sciences
3.6%
UTHRCALL
United Therapeutics
3.3%
UTHR
United Therapeutics
3.2%
BNTXCALL
BioNTech
3.1%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.